Analyst David Moskowitz joins Unigene as CFO
This article was originally published in Scrip
Peptide-based therapeutics developer Unigene Laboratories has appointed David Moskowitz to the newly created position of CFO. He joins the company after 13 years as a research analyst covering large-cap pharmaceutical and speciality pharmaceutical, biotechnology, and generic drug companies. He most recently served as senior pharmaceutical analyst for Roth Capital Partners where he developed research coverage of emerging speciality pharma and biotech companies.